611 related articles for article (PubMed ID: 33451333)
1. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.
Du R; Huang C; Liu K; Li X; Dong Z
Mol Cancer; 2021 Jan; 20(1):15. PubMed ID: 33451333
[TBL] [Abstract][Full Text] [Related]
2. Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.
Yan M; Wang C; He B; Yang M; Tong M; Long Z; Liu B; Peng F; Xu L; Zhang Y; Liang D; Lei H; Subrata S; Kelley KW; Lam EW; Jin B; Liu Q
Med Res Rev; 2016 Nov; 36(6):1036-1079. PubMed ID: 27406026
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase A in gastrointestinal cancers: time to target.
Katsha A; Belkhiri A; Goff L; El-Rifai W
Mol Cancer; 2015 May; 14():106. PubMed ID: 25987188
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
[TBL] [Abstract][Full Text] [Related]
5. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
6. Insights into the non-mitotic functions of Aurora kinase A: more than just cell division.
Bertolin G; Tramier M
Cell Mol Life Sci; 2020 Mar; 77(6):1031-1047. PubMed ID: 31562563
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy.
de Souza VB; Kawano DF
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129448. PubMed ID: 31676293
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
9. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
11. Issues in interpreting the in vivo activity of Aurora-A.
Shagisultanova E; Dunbrack RL; Golemis EA
Expert Opin Ther Targets; 2015 Feb; 19(2):187-200. PubMed ID: 25384454
[TBL] [Abstract][Full Text] [Related]
12. AURORA KINASE A and related downstream molecules: A potential network for cancer therapy.
Fatma H; Siddique HR
Adv Protein Chem Struct Biol; 2023; 134():115-145. PubMed ID: 36858732
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinases: novel therapy targets in cancers.
Tang A; Gao K; Chu L; Zhang R; Yang J; Zheng J
Oncotarget; 2017 Apr; 8(14):23937-23954. PubMed ID: 28147341
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
[TBL] [Abstract][Full Text] [Related]
15. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
16. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase A inhibitors: promising agents in antitumoral therapy.
Malumbres M; Pérez de Castro I
Expert Opin Ther Targets; 2014 Dec; 18(12):1377-93. PubMed ID: 25200357
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinase A, a synthetic lethal target for precision cancer medicine.
Mou PK; Yang EJ; Shi C; Ren G; Tao S; Shim JS
Exp Mol Med; 2021 May; 53(5):835-847. PubMed ID: 34050264
[TBL] [Abstract][Full Text] [Related]
19. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
[No Abstract] [Full Text] [Related]
20. Mechanisms for nonmitotic activation of Aurora-A at cilia.
Korobeynikov V; Deneka AY; Golemis EA
Biochem Soc Trans; 2017 Feb; 45(1):37-49. PubMed ID: 28202658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
